BIOAVAILABILITY ENHANCEMENT – Overcoming Poorly Soluble Pharmaceutical Formulations With Hot Melt Extrusion
INTRODUCTION Solubility is an essential characteristic of active pharmaceutical ingredients (APIs), with profound effects on process and clinical development, formulation, and commercialization. Higher-solubility drugs dissolve…
FORMULATION DEVELOPMENT – Recombinant Human Albumin: Delivering the Future of Type 2 Diabetes Medication
Mark Perkins, PhD, discusses the application of human serum albumin as a half-life extension technology for GLP-1 therapeutics and how further developments in recombinant human albumin technology may further change the dosing paradigm.
EXECUTIVE INTERVIEW – DPT Laboratories: Providing Solutions to Sterile & Non-Sterile Development & Manufacturing of Semi-Solid & Liquid Dosage Forms
Paul Johnson, DPT Group President & Chief Operating Officer, talks about the consistent growth and success of DPT, its expansion in the sterile arena, and plans for the future.
DRUG DELIVERY – Hyaluronic Acid: An Ideal Ingredient for Slow-Release Formulations for Osteoarthritis Treatment
Morten J. Maltesen, PhD; and Ole M. Dall, MSc; believe that in addition to its physiological and biological effects in the joints, HA exhibits significant structural and rheological properties that make it an attractive carrier for drug delivery applications.
DRUG DESIGN – Fragment-Based Drug Design: Delivering Drugs That Hit Multiple targets, Leveraging Insights From Systems Biology
David Pompliano, PhD, believes the next generation of pharmaceuticals will have to hit more than one target simultaneously in order to fully exploit the knowledge gained from systems biology, and currently, the most effective strategy to achieve this rational design goal is computational fragment-based drug design (CFBDD).
ANALYTICAL TESTING – Analytical Tools & Techniques in Hot Melt Extrusion & Case Studies on Formulation Development & Process Scale-Up
Tony Listro, MS, MBA; Mike Borek, Michael Crowley, PhD, MBA; and Kathrin Nollenberger, PhD; review how a stepwise approach to characterizing formulation prototypes using microscopy, thermal analysis, spectroscopy, nonsink dissolution testing, and chromatography can be used to rapidly rank order formulations.
Jean C. Sung, PhD, says that while delivery of drugs via first-generation inhaled drug systems provides great advantages over oral or intravenous delivery, these systems also have inherent limitations, creating a tremendous opportunity for next-generation inhaled delivery platforms.
EXECUTIVE INTERVIEW – Accera, Inc: Discovering Breakthroughs in Treating Central Nervous System Disorders
Holger Kunze, CEO of Accera, discusses the company’s novel approach to treating AD by addressing cerebral hypometabolism.
BIOAVAILABILITY ENHANCEMENT – Addressing Solubility Challenges: Using Effective Technology & Problem-Solving for Delivery Solutions
Rod Ray, PhD, reviews his spray-dried dispersion (SDD) technology, which is recognized as a reliable solution to oral bioavailability challenges because of its proven performance, predictable long-term stability, and excellent manufacturability.
EXECUTIVE INTERVIEW – Caisson Biotech: Innovatio in Drug Delivery Using a Naturally Occurring Sugar Molecule
Thomas Harlan, CEO of Caisson, discusses how his company is improving the quality and delivery of numerous medications, making life easier for patients, and offering new ways for companies to enhance their drug pipeline.
EXCLUSIVE ONLINE CONTENT
Kymab & LifeArc Enter Strategic Partnership to Discover New Medicines Using Kymab’s IntelliSelect Technologies
The agreement will enable LifeArc to enhance its antibody drug discovery capabilities into new medicinal products with Kymab’s proprietary IntelliSelect technology platforms.
Loxo Oncology, Inc. recently entered into a strategic partnership agreement with Amoy Diagnostics Co., Ltd. and PREMIA Holdings (HK) Ltd.
Aclaris Therapeutics, Inc. recently announced positive results from a Phase 2 open-label clinical trial of ATI-502 (AGA-201), an investigational topical Janus Kinase (JAK) 1/3 inhibitor, in patients with androgenetic alopecia (AGA), a condition commonly known as male/female-pattern baldness.
iBio, Inc. recently announced the activation of its new cGMP sterile fill-finish services operation via the signing of a supply agreement with a clinical-stage biopharmaceutical company developing breakthrough gene and cell therapies.
Gilead Sciences, Inc. and Nurix Therapeutics, Inc. recently announced a global strategic collaboration to discover, develop, and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases.